GET DAILY SIGNALSAvidity Biosciences (RNA) Falls -34.7% After Phase III Setback
Key Takeaways
- Avidity Biosciences (RNA) shares fell approximately 34.7% over the trailing 30 days, declining from a closing price of $13.71 on August 19, 2026, to $8.95 on September 18, 2026.
- The move was driven primarily by a September 8 setback for del-desiran, the lead antibody-oligonucleotide conjugate (AOC) candidate built on Avidity's platform, which missed its primary endpoint in the Phase III HARBOR study for myotonic dystrophy type 1 (DM1).
- The sell-off pushed RNA toward its 52-week low and below key longer-term moving averages, reflecting a broader repricing of the AOC platform's clinical validation outlook.
- Second-quarter results reported on August 13 exceeded estimates, but the favorable earnings update was overshadowed by the later clinical disappointment.
- Investor attention now turns to the remaining AOC pipeline programs and upcoming development milestones.
Avidity Biosciences (RNA) Company Background
Avidity Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in La Jolla, California, focused on developing antibody-oligonucleotide conjugate (AOC) therapies for serious neuromuscular and cardiac diseases. Its proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides, with the goal of delivering RNA-based therapeutics directly into muscle cells—an area historically difficult to reach with conventional drug-delivery methods. Investors follow RNA because the company's platform represents an attempt to expand RNA therapeutics beyond the liver and validate a new delivery mechanism across multiple rare and genetic diseases.
Recent Stock Performance: The -34.7% Decline
Over the last 30 days, RNA declined roughly 34.7%, falling from a $13.71 close on August 19, 2026, to $8.95 on September 18, 2026. The decline was heavily concentrated in a single stretch: the stock opened the September 4 session near $14 and fell sharply beginning September 8, when trading volume surged and the shares broke below multiple technical levels.
The broader quarter tells a similar but more volatile story. After opening the third quarter near the mid-$13 range, RNA drifted lower into the low-$11 area in late July, recovered to about $14.60 by early September, and then sold off to roughly $9 following the clinical setback. The result was a peak-to-trough decline of roughly 38% within the quarter, leaving the stock trading near its 52-week low.
The Primary Catalyst for the Recent Drop
The dominant catalyst was the September 8 announcement that del-desiran (delpacibart etedesiran), the lead AOC candidate originating from Avidity's platform, failed to meet its primary endpoint in the global Phase III HARBOR study for myotonic dystrophy type 1. The trial, which evaluated the therapy against placebo using video hand opening time as its primary measure, did not demonstrate a statistically significant improvement. The company noted evidence of clinical activity in secondary and exploratory analyses, but the miss represented a meaningful validation setback for the AOC platform and prompted analysts to lower peak-sales expectations.
The read-through extended beyond Avidity itself. The AOC failure weighed on sentiment across the RNA-therapeutics and neuromuscular space, pressuring peers such as Dyne Therapeutics (DYN) and contributing to a reassessment of related cardiovascular RNA programs. The broader biotechnology sector also faced volatility during the period, which amplified the decline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Quarter Performance and Earnings Context
Before the September sell-off, RNA's third quarter was shaped by a mix of company-specific and sector-level forces. On August 13, Avidity reported a narrower-than-expected quarterly loss of $1.18 per share versus a consensus estimate of a $1.42 loss, while revenue of $3.0 million surpassed the roughly $0.67 million consensus. The earnings beat supported a brief recovery into the mid-$14 range. However, the later Phase III HARBOR result reframed the quarter's narrative, as investors shifted from near-term financials to the longer-term question of whether the AOC platform can convert promising early-stage biomarker signals into successful late-stage clinical outcomes.
Key Factors Investors Should Watch
Looking ahead, investors will monitor several factors. First, the complete HARBOR dataset and any regulatory feedback will be important, as the company indicated it would engage with health authorities to determine the next steps for del-desiran. Second, progress on the remaining AOC pipeline programs will be closely watched, since they now carry a larger share of the platform's value proposition. Third, quarterly earnings and cash-position updates will matter for a clinical-stage company that relies on continued funding to advance its programs. Finally, broader sector dynamics—including risk appetite for clinical-stage biotechnology and any peer read-throughs from RNA-therapeutics programs—will continue to influence RNA's trading range.
Exploring Trending AI Robots
I often turn to Tickeron’s Trending AI Robots page when evaluating how automated strategies are positioning around names like RNA. The section curates top-performing bots from a large universe, offering a practical way to see algorithmic activity across stocks and timeframes without having to build models from scratch.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
RNA's RSI Indicator climbs out of oversold territory
The RSI Indicator for RNA moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In 28 of the 33 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for RNA just turned positive on October 07, 2026. Looking at past instances where RNA's MACD turned positive, the stock continued to rise in 29 of 38 cases over the following month. The odds of a continued upward trend are 76%.
Following a +0.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNA advanced for three days, in 197 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 61 cases where RNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RNA as a result. In 75 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for RNA entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.665) is normal, around the industry mean (3.498). P/E Ratio (-1.533) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.537) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. RNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in the research and development of biopharmaceutical products
Industry Biotechnology
Advertisement